Overall, these converging multi-omics findings highlight AP1AR and AP1S3 as the most clinically relevant AP-1 adaptors in lung cancer, elucidating their roles in proliferation, stress adaptation, immune modulation, and drug response. Here, AP1AR is linked to lung carcinoma.